Scinai Appoints Eilon Elmalem as Yavne CDMO Site Head Effective June 14, 2026
SCNI•Scinai Biopharma Services has appointed Eilon Elmalem as Site Head of its Yavne CDMO facility, effective June 14, 2026, where he will oversee operations and engineering activities. Elmalem brings over 20 years of biopharma engineering and operations leadership from roles at Merck and Sigma-Aldrich Millipore, supporting planned facility expansion.
1. Leadership Appointment
Scinai Biopharma Services has named Eilon Elmalem as Site Head of its recently acquired Yavne CDMO facility, with the role commencing June 14, 2026. In this capacity, he will assume full responsibility for site operations, engineering activities and ongoing integration efforts following the Recipharm acquisition.
2. Operational and Technical Expertise
Elmalem brings over two decades of experience in biopharmaceutical engineering, process development and industrial infrastructure management. His previous senior leadership roles at Merck and Sigma-Aldrich Millipore involved overseeing R&D, manufacturing and major capital investment programs across Israel, Europe and the United States.
3. Transition Process and Strategic Outlook
The transition under current site head Dr. Sylvia Kachalsky began May 10 and aims to ensure continuity ahead of her retirement later in 2026. This leadership change is designed to bolster Scinai’s CDMO operational excellence and support the planned expansion of the Yavne facility.
